Tetracycline

證據等級: L5

預測適應症: 4 個

Tetracycline: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Tetracycline is a classic broad-spectrum bacteriostatic antibiotic widely used to treat bacterial infections caused by gram-positive, gram-negative, and intracellular pathogens — most notably Chlamydia trachomatis, for which it remains a first-line agent. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis (PEK), with 0 clinical trials and 1 publication currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Bacterial infections (broad-spectrum antibiotic; first-line for chlamydial infections)
Predicted New Indication	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.58%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Detailed mechanism of action data is not currently available in this evidence pack. Based on established pharmacology, Tetracycline is a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the ribosome–mRNA complex. This mechanism is particularly effective against intracellular organisms, making tetracycline a cornerstone treatment for Chlamydia trachomatis infections.

Punctate epithelial keratoconjunctivitis (PEK) is a corneal surface condition characterised by scattered epithelial defects detectable by fluorescein staining. One established aetiology is chlamydial infection: PEK lesions can persist or recur as a sequela of C. trachomatis follicular conjunctivitis, even after resolution of active conjunctival inflammation. In this light, the mechanistic link between tetracycline and PEK is indirect — by eradicating the underlying chlamydial trigger, tetracycline could allow the damaged ocular surface to heal.

It is critical to note that the single available publication describes PEK as a complication observed after tetracycline treatment of chlamydial conjunctivitis, not a condition that tetracycline was directly used to treat. There is no interventional evidence of tetracycline targeting PEK as a primary indication, nor data on non-chlamydial PEK aetiology.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1424659	1992	Case Series	Cornea	Two patients developed persistent bilateral punctate epithelial keratitis following chlamydial follicular conjunctivitis treated with oral tetracycline or doxycycline; recurrent grayish corneal epithelial lesions and anterior stromal oedema were observed post-follicle resolution, suggesting PEK as a post-infectious sequela rather than a direct treatment target

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The only supporting publication is a 1992 case series documenting PEK as an outcome following tetracycline therapy for chlamydial conjunctivitis — not a study evaluating tetracycline as a treatment for PEK. With zero clinical trials and a single observational case report of limited relevance, the evidence base is insufficient to support advancing this indication.

To proceed, the following is needed:

Prospective clinical studies directly evaluating tetracycline or doxycycline as treatment for PEK (particularly in chlamydial-associated cases)
Mechanism of action (MOA) data from DrugBank (currently unavailable — DG002)
Philippines FDA package insert data and safety/contraindication review (currently unavailable — DG001)
Clarification of target population: PEK secondary to active chlamydial infection (biologically plausible indirect mechanism) vs. PEK of other aetiologies (no mechanistic support identified)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.